With important effects on neuronal lipid composition, neurochemical signaling and cerebrovascular pathobiology, docosahexaenoic acid (DHA), a n-3 polyunsaturated fatty acid, may emerge as a neuroprotective agent against cerebrovascular disease. This paper examines pathways for DHA accretion in brain and evidence for possible roles of DHA in prophylactic and therapeutic approaches for cerebrovascular disease. Recent findings DHA is a major n-3 fatty acid in the mammalian central nervous system and enhances synaptic activities in neuronal cells. DHA can be obtained through diet or to a limited extent via conversion from its precursor, a-linolenic acid (a-LNA). DHA attenuates brain necrosis after hypoxic ischemic injury, principally by modulating membrane biophysical properties and maintaining integrity in functions between presynaptic and postsynaptic areas, resulting in better stabilizing intracellular ion balance in hypoxicischemic insult. Additionally, DHA alleviates brain apoptosis, by inducing antiapoptotic activities such as decreasing responses to reactive oxygen species, upregulating antiapoptotic protein expression, downregulating apoptotic protein expression, and maintaining mitochondrial integrity and function. Summary DHA in brain relates to a number of efficient delivery and accretion pathways. In animal models DHA renders neuroprotection after hypoxic-ischemic injury by regulating multiple molecular pathways and gene expression.
Introduction
Cerebrovascular disease encompasses diseases of the blood vessels supplying the brain, and is associated with stroke. In the USA, stroke represents the third major cause of death in adults, affecting over 800 000 persons per year [1] . Ischemic stroke, the predominant stroke subtype in many populations, has defined risk factors that can, in part, be effectively reduced through preventive regimens [1, 2] . Diet intervention is one example that may impact upon risk factors for stroke [3] .
Some but not all human prospective studies indicate that frequent fish consumption may ameliorate the risk of stroke, especially ischemic stroke [4] [5] [6] [7] . Long-chain n-3 polyunsaturated fatty acids (n-3 FA), especially eicosapentaenoic acid (EPA, C20 : 5 n-3) and docosahexaenoic acid (DHA, C22 : 6 n-3) which are found in high concentration in marine foods, are suggested to be the nutrients underlying neuroprotection [8, 9] . Evidence from experimental studies both in humans and animal models demonstrates that n-3 FA modulate mechanisms of development and progression of stroke, with effects on membrane fluidity, cell signaling and gene transcription [10] [11] [12] . n-3 FA also decrease other stroke-related risk factors such as high blood pressure, arrhythmias, abnormal lipid profiles, platelet aggregation, endothelial function, and atherosclerotic processes [13] [14] [15] [16] . Of note, n-3 FA are catabolized to produce promisingly neuroprotective catabolites such as neuroprotectin D1 (NPD1) [17] .
Studies on DHA-mediated neuroprotection have prompted the following questions: in the absence of dietary DHA, can cerebral DHA levels be maintained? By what mechanisms does DHA provide neuroprotection? The aim of the present review is to highlight recent findings on accretion of n-3 FA and how this might relate to protective effects after hypoxic ischemic injury (H/I) in Table 1 summarizes six epidemiological studies, one meta-analysis and one interventional study on fish consumption and n-3 FA in humans. Some of these studies provide evidence for benefit of n-3 FA in affecting stroke outcomes [5, 8, 18] . Bouzan et al. [19] evaluated a doseresponse relationship between fish consumption and stroke risk from their meta-analysis. Results indicated a small relative risk reduction after fish consumption compared to no fish consumption. The Japan EPA Lipid Intervention Study (JELIS) on cardiac events [20] also evaluated the effect of EPA on the primary and secondary prevention of stroke in hypercholesterolemic patients receiving statin only or statin with EPA. The results showed that in the primary prevention subgroup, EPA had no preventive effect on total stroke. Interestingly, in the secondary prevention subgroup, a significant 20% reduction in the recurrence of stroke in the EPA group was observed. Some studies do not demonstrate a beneficial association between fish consumption and stroke risk [7, 21, 22] . Some of these studies were performed in Japanese and Swedish populations with high baseline intakes of fish and n-3 FA so that additional n-3 FA intakes might not be helpful. Studies of increased n-3 FA intakes in the USA, and some other populations appear to provide mild to moderate protection. Thus, evidence is mixed as to the possible benefits of n-3 FA rich diets or n-3 FA supplements on stroke outcomes in humans.
Polyunsaturated fatty acids in brain
Brain contains the highest concentration of lipids of all organs except adipose tissue. More than one-third of these lipids are very long chain polyunsaturated acids such as DHA and arachidonic acid (20 : 4 n-6) [23] . DHA is the most abundant n-3 FA in the mammalian central nervous system, specifically concentrating in lipid bilayer membranes of brain grey matter and retinal membranes [24, 25] . The incorporation of n-3 FA into neuronal membranes leads to increased membrane fluidity which can increase the number and affinity of receptors in synaptic regions and improve neurotransmission [26] . The levels of DHA in the brain increase during development [27] and decrease with aging [24] . When n-3-FA and n-6 FAcontaining foods are consumed, n-3 and n-6 FA interact and may compete with each other in fatty acid metabolic pathways and in pathways of incorporation into cells, Docosahexaenoic acid, protection in stroke Mayurasakorn et al. 159 Table 1 Summary of studies reporting n-3 FA or fish intake and stroke outcome in humans
Author
Study design, sample size Results (RR, hazard ratio, OR, CI)
Prospective cohort study in the USA of 4775 adults aged 65 years or older and free of cerebrovascular disease at baseline, 12 years of follow-up
Inverse correlation between consumption of tuna/other kinds of fish and total stroke (P ¼ 0.04) and ischemic stroke (P ¼ 0.02), with 27% lower risk of ischemic stroke with intakes of 1 to 4 times per week (hazard ratio, 0.73; 0.55-0.98) and 30% lower risk with intakes of five or more times per week (hazard ratio, 0.70; 0.50-0.99) compared with an intake of less than once per month Yamagishi et al. [7] Prospective cohort study in Japan of 57 972 men and women aged 40-79 years, 12.7 years of follow-up
Neither fish nor n-3 FA dietary intake was associated with differences in mortality from stroke leading to varying levels in brain tissues and other organs [25] . In animal models and perhaps humans, low or very low dietary consumption of n-3 FA or low plasma DHA concentration is associated with impaired neurogenesis, altered metabolism of several neurotransmitters, membrane receptors, gene expression and impaired learning performance in the developing brain and in aging [25, [28] [29] [30] [31] .
n-3 fatty acid levels in brain DHA, and also arachidonic acid, must be obtained through the diet or via conversion from their respective shorter-chain essential fatty acid precursors, a-linolenic acid (a-LNA, 18 : 3 n-3) and linoleic acid (18 : 2 n-6), respectively (Fig. 1) . These precursors cannot be synthesized de novo in vertebrate tissue due to the absence of the required 12-desaturase and 15-desaturase enzymes [34 ] . In mammals, both a-LNA and linoleic acid can be physiologically metabolized into longer carbon chains via desaturation and elongation pathways by using common enzymes (Fig. 1) . The conversion of dietary a-LNA into EPA and DHA is inefficient [10, 35] . For example, supplementing a-LNA during pregnancy does not increase circulating DHA levels in maternal or newborn infant blood lipids [35] , whereas dietary intakes of DHA positively relate to blood circulating DHA levels [36] . Thus, if an individual's intake of DHA-containing food is low, how does the brain conserve DHA at levels that allow the brain to have normal function? Also, how does brain DHA accretion depend upon dietary FA composition and the liver's ability to convert a-LNA to DHA?
In animal models, high intakes of linoleic acid impede desaturation of a-LNA into EPA and further into DHA, and increase docosatetraenoic acid (22 : 4 n-6) and docosapentaenoic acid (22 : 5 n-6) levels, which leads to reduced accretion of DHA in the brain, retina, and other organs [25] . Conversely, increasing a-LNA consumption appears to result in enhancement of DHA content [34 ] . Liou et al. [37] demonstrate that decreasing linoleic acid consumption (to the ratio 4 : 1 of linoleic acid : a-LNA) results in higher EPA levels in plasma phospholipids and lower arachidonic acid levels when compared to a higher linoleic acid diet. Thus, a number of papers suggest that decreasing amounts and ratios of linoleic acid intakes compared to a-LNA, EPA, and DHA intakes will lead to higher accretion of EPA and DHA [31, 38, 39] . Evidence in animals demonstrates that high proportions of DHA are still present in brain phospholipids even in herbivores that consume no DHA and have low levels of plasma and liver DHA [25] . When intake of DHA is limited as shown by low circulatory levels of DHA, DHA can still be found at normal levels in brain tissue [25] .
Can brain docosahexaenoic acid levels be maintained in the absence of dietary docosahexaenoic acid?
Because of the importance of DHA to brain metabolism and function, and the low conversion (<1%) of circulating a-LNA into DHA, humans should consume more DHAcontaining marine foods [40] [41] [42] . b-Oxidation of most dietary a-LNA for energy occurs before quantitatively desaturating to DHA [36] . DHA brain concentrations relate to diet and to liver synthesis [34 ] . Rapoport et al. [34 ] have concluded from 15-week dietary studies in rats that normal brain DHA levels can be maintained by hepatic conversion and secretion of DHA derived from circulating a-LNA if sufficient amounts of a-LNA are provided in the diet. The brain's capacity for conversion is much less [34 ,43] . Compared to a diet high in DHA a
Figure 1 Extracellular trafficking of docosahexaenoic acid
The liver takes up docosahexaenoic acid (DHA) and a-linolenic acid (a-LNA) supplied by diet, and elongates and desaturates a-LNA to DHA, which is then delivered to blood as nonesterified fatty acid bound to albumin, or DHA-esterified phospholipids. After DHA is delivered to brain endoplasmic reticulum, it is activated to docosahexaenoyl-CoA by an acyl-CoA synthetase (ACS), then esterified into membrane lysophospholipid (LPL) by an acyltransferase (AT). After hypoxic-ischemic insult, free DHA is derived from membrane DHA stores, which are liberated via PLA2 cleavage and may be converted into the 10,17S docosatriene, NPD1, through an enzyme-mediated lipoxygenation via 15-LOX, or 15-LOX-like enzymes [32, 33] .
DHA-free diet together with very low levels of a-LNA reduced DHA concentrations in brain phospholipids by 56%, and a DHA-free diet in combination with high a-LNA reduced the brain phospholipid DHA concentration by only 32%. This result is analogous to human studies in which plasma DHA in patients who ate meat and fish was proportionately 31 and 59% higher than in the vegetarians (who consumed no meat or fish) and vegans (who did not eat any animal-origin foods), respectively [43] . Potential underlying reasons why brain DHA concentration may be maintained even in prolonged periods of DHA-deprived settings include: higher liver (but not brain) conversion of a-LNA via (increased expression of liver elongases 2, 5, D5, and D6 desaturases) [44] [45] [46] and the half-life of brain DHA is prolonged by downregulating expression of DHA-metabolizing enzymes, namely Ca 2þ -independent phospholipase A 2 (iPLA 2 ) and cyclooxygenase-1 [38, 47, 48] . Also, n-3 FA deprivation leads to upregulating arachidonic acid metabolism as shown by increased brain mRNA, protein and activity levels of arachidonic acid-selective phospholipase A 2 and COX-2-enzymes that are directly involved in brain arachidonic acid metabolism [49] . These pathways can contribute to neuronal damage [38] . Still, some do not agree that DHA synthesis from a-LNA is insufficient to maintain adequate DHA levels [47, 50] . Therefore, it is possible that a-LNA will emerge as an alternative source of dietary n-3 FA in settings where dietary DHA is low.
Mechanisms of neuronal cell death following hypoxia-ischemia
There are multiple interrelated mechanisms that contribute to progressive brain damage during the initial hours after ischemic stroke. Ischemia leads to a reduction of up to 80% in cerebral blood flow in 'core' tissue, leading to a disruption of delivery of glucose and oxygen to cells for ATP generation [51, 52 ]. The mechanisms of neuronal cell death in animals and humans after H/I can be categorized into two major phases, neuronal necrosis during acute insult, and neuronal apoptosis during a recovery period following circulatory restoration, often termed reperfusion injury [51, 53] . Necrosis relates to a passive process of cell swelling resulting from an imbalance of intracellular ions, especially Na þ , K þ , Ca 2þ ions, with a disruption of cytoplasmic organelles, loss of membrane integrity resulting from overloads of Ca 2þ influx to cells, and an activation of inflammatory enzymes such as cyclooxygenases. Processes leading to necrosis occur within the first few minutes after ischemia and continue for hours. Apoptosis is an active process, and includes cell shrinkage, nuclear pyknosis, chromatin condensation, and genomic fragmentation [51] . These apoptotic processes occur within several hours to days/ weeks after H/I. Neuroprotective studies in cell and animal models have been directed toward prevention of both mechanisms.
Neuroprotective properties of docosahexaenoic acid
Exact mechanisms by which DHA exerts neuroprotective effects are not fully defined. DHA is believed to affect multiple pathways. It is generally assumed that the transport of fatty acids to brain occurs from the nonesterified fatty acid pool (NEFA) bound to serum albumin (Fig. 1) . However, a recent finding suggests that lipoproteins with DHA-acylated phospholipids may also selectively deliver DHA to brain and other tissues [32] . Also, lysophosphatidylcholine (LysoPC), produced by lecithin cholesterol acyl transferase (LCAT) may be another form of targeted transport of DHA to brain [54 ] .
Our understanding of the potential role of DHA in stroke originates from in-vitro cell systems, and in vivo, animal models of hypoxic-ischemic brain [10,17,32,33,34 ,36, 39,55-64] . The pathways and mechanisms presented below are summarized in Fig. 2 and in Table 2 . 'Beneficial' effects of DHA in preventing and ameliorating stroke have been attributed to their stereospecific derivative, NPD1 [17, 32, 55, 56] . 'Positive' regulatory actions of DHA and NPD1 likely occur via several interdependent mechanisms (Fig. 2) . Under basal conditions in brain, the amount of free DHA is low or negligible and its level is tightly controlled by the action of phospholipase A 2 and DHA removal [55, 65] . During brain ischemia and reperfusion (I/ R), in human brain cells [61, 66, 67] , DHA is cleaved from membrane phospholipids to free (unesterified) DHA by phopholipase A 2 , and free DHA is then converted into NPD1 by lipoxygenation catalyzed by 15-lipoxygenase-1 (15-LOX-1) [17] . NPD1 forms in the ipsilateral side of ischemic brain and peaks at 8 h of reperfusion, and then decreases, and is still detected at 25 h after reperfusion [66] . Although DHA in brain can produce NPD1, additional DHA from acute administration is likely beneficial. For instance, one study indicated that cerebroventricular-infused NPD1 (400 ng over 48 h) in adult mice elicited substantial protection against ischemia and leukocyte infiltration compared to control mice [66] . Hence, it is possible that endogenously generated NPD1, released from cerebral membrane phospholipids, is not sufficient to counteract ischemic injury especially when the injury is severe [66] . In in-vivo experiment-induced liver injury, dietary supplementation of mice with DHA increased hepatic formation of NPD1 [68] . However, it is not known if cerebral NPD1 can be supplied from DHA conversion in liver after brain ischemia.
Formation of NPD1 from DHA is upregulated by many factors such as increased oxidative stress, mediated by H 2 O 2 , tumor necrosis factor a [69] , I/R [66] , Ca 2þ ionophore A23187 [69] , and interleukin (IL)-1b activity [56, 69] . Neuroprotective properties may be facilitated through antinecrotic pathways such as decreasing the production of n-6 FA [58] , enhancing function of Na þ /K þ channels [39] , enhancing affinity of receptors and improving neurotransmission [59, 70] . Furthermore, they may be mediated through antiapoptotic functions via inducing antiapoptotic proteins and inhibiting apoptotic proteins [32, 63, 71, 72] , improving mitochondrial function [56] , diminishing formation of free radicals [63] , and decreasing cell inflammation [63, 66] , all resulting in the reduction of brain infarction [39, 57, 58, 63, 73, 74] .
Production of arachidonic acid
Arachidonic acid competes with DHA for incorporation into cell membrane phospholipids. Under physiological conditions, PLA 2 liberates arachidonic acid from membrane phospholipids at a rate that balances the rate of arachidonic acid reincorporation into the membranes, resulting in low levels of free arachidonic acid [58] . Arachidonic acid is oxidized by lipooxygenases and further by cyclooxygenases producing prostaglandins, leukotrienes, thromboxanes, and other bioactive eicosanoids, several of which have been implicated in brain damage following I/R [17, 75] . n-6 FA may negatively affect outcomes after ischemic insult or injury [58, 76] . Modification of dietary fatty acid composition by consuming DHA-containing diets or via DHA supplementation may increase DHA esterification into cellular phospholipids. In support of this latter finding, Cao et al. [58] found that in an animal model a 10-week supplement of ethyl-DHA significantly decreased the content of brain lipid arachidonic acid, thereby diminishing postischemic arachidonic acid-derived eicosanoid production, which was associated with preserved cerebral blood flow and attenuated cerebral edema.
Ionic homeostasis
With ischemic insult, there is an interruption of blood supply (followed by decreasing glucose and oxygen levels)
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Figure 2 Neurochemical changes and mechanistic actions of docosahexaenoic acid contributing to neuroprotection after cerebral ischemia
After ischemic insult, docosahexaenoic acid (DHA) cleaved by phospholipase A 2 synthesizes NPD1, a stereospecific derivative of DHA through an action of a lipoxygenase enzyme (15-LOX-1). NPD1 provides antinecrotic and antiapoptotic activities. In 'antinecrosis', NPD1 and/or DHA enhances membrane integrity by mediating Na þ -K þ pumps, Na þ -Ca 2þ pumps and N-methyl-D-aspartate (NMDA) receptors, leading to less influx of Na þ , Ca 2þ , and improved glutamatergic synaptic activity. These properties prevent water from flowing into the cells due to osmotic gradients, contributing to less edema and antinecrosis. In antiapoptosis, NPD1 and/or DHA improves mitochondrial function for coping with reactive oxygen species (ROS) by increasing antioxidant activities, upregulates the Bcl-2 family of antiapoptotic proteins including the members Bcl-2, Bcl-xL, Bcl-w, Bfl-1(A1), downregulates cytochrome c, caspase-3 in DHA-cultured neurons, and proapoptotic signaling proteins including Bax, Bad, Bid and Bik. In addition, the production of proinflammatory eicosanoids such as IL-1b, COX-2, CEX-1 is also impeded (references in text).
to the brain that leads to ATP depletion. Arachidonic acid requires ATP for its metabolism after liberation from cell membranes. Hence, during ischemia, free arachidonic acid and its metabolites accumulate in the cytoplasm, which induce pathophysiological events such as impairment of ion channels, and other membrane-associated enzymes, particularly Na þ -K þ ATPase activity [75] . The fall in Na þ -K þ ATPase activity also results from other causes, such as a decline of ATP content itself and increased production of other enzymatic inhibitors. Free arachidonic acid and prostaglandins are examples of potent Na
ATPase inhibitors [60, 77] . The decline of Na
ATPase activity can also lead to ionic imbalance, causing cellular edema due to a rapid loss of K þ and influx of Na þ from neurons and neuronal depolarization. Increased intracellular Na þ causes cells to internalize Ca 2þ , contributing to intracellular Ca 2þ overload [78] . Cao et al. [39] suggest that dietary DHA reduces postischemic cerebral edema by maintaining Na þ -K þ ATPase function from declining after ischemia, as shown by lower intracellular Na þ , but higher K þ content than those in vehicle-treated animals (Fig. 2) .
Glutamate and glutamate receptors
Glutamate functions as a major neurotransmitter which is abundant in the central nervous system (CNS). Glutamate is involved in learning/memory, brain development and aging [70, 79] . However, increased amounts of glutamate in the synaptic cleft can cause neurotoxicity due to overstimulation of glutamate receptors [70, 80] . Glutamate levels are mediated by a number of receptors, such as N-methyl-D-aspartate (NMDA) receptors, which lead to both agonistic and antagonistic properties for glutamate. Following the rise in intracellular Ca 2þ concentration after ischemic insult, excitatory amino acids including glutamate, are released from axon terminals. Impaired reuptake at presynaptic nerve endings into the extracellular space together with the continuous stimulation of the NMDA receptors of the agonist-operated Ca 2þ channel by glutamate also leads to accumulation of Ca 2þ in cell cytoplasm. Ca 2þ is also released into cytoplasm from mitochondria by the Na þ /H þ -dependent antiport system and other organelles [78] , which leads to irreversible brain damage [81] . Moreover, ischemiainduced glutamate release causes the activation of PLA 2 , which results in further membrane-bound phospholipid degradation and arachidonic acid liberation [82] . Within the cytoplasm these free fatty acids undergo peroxidation by reactive oxygen species (ROS) produced from ischemic insult. In selected neurons, intracellular Ca 2þ induces the production of nitric oxide, a free radical that diffuses to adjacent cells susceptible to nitric oxide toxicity, and enhances glutamate release. All of these mechanisms can contribute to the cycle of cell necrosis and further the process of apoptosis [51] .
Moreira et al. [70] reported that in DHA-treated rats glutamate equilibrium is better preserved than in DHA-deprived rats after ischemia. Cao et al. [59] demonstrated in chronic (but not acute) DHA-supplemented hippocampal neurons, spontaneous synaptic activity is significantly increased due to increased synapsins, and glutamate receptor subunit (NR and GluR) levels [59] , suggesting a unique role of DHA in promoting active synapse formation and/or presynaptic neurotransmitter release. The mechanisms by which DHA can block ionotropic glutamate receptors are also supported by other studies [83, 84] . As the synaptic activity is activated by chronic intakes of DHA, supplements of DHA in immature brain and stroke-related risk individuals may be an important aspect of ultimately enhancing excitatory synaptic activity for prevention of stroke.
Proapoptotic and antiapoptotic proteins
Key proapoptotic and antiapoptotic members of Bcl-2 gene family regulate the fate of brain cells. These proapoptotic molecules induce, but antiapoptotic molecules inhibit the release of mitochondrial-bound cytochrome c
Relevant references are provided in the text. DHA, docosahexaenoic acid; ROS, reactive oxygen species.
into cytosol. Cytochrome c activates proapoptotic caspases, such as caspase-3 and caspase-9, leading to apoptosis and cellular death [72] . DHA or NPD1 upregulates the Bcl-2 family of antiapoptotic proteins including the members Bcl-2, Bcl-xL, Bcl-w, Bfl-1(A1), but downregulates caspase-3 and caspase-9, apoptotic proteins in DHAcultured neurons, and proapoptotic signaling proteins including Bax, Bad, Bid and Bik [32, 67, 71] . Pan et al. [63] have found that both acute and chronic DHA pretreatment before ischemia insult attenuate cerebral-I/Rinduced caspase-3 activity as well as oxidative burden as shown by the reduction of lipid peroxidation products that are capable of generating reactive oxygen-free radicals. Surprisingly, acute DHA administration had little effect on expression of Bcl-2 proteins, but chronic administration showed higher levels of Bcl-2 proteins. In parallel with these benefits on Bcl-2 family gene expression, NPD1 impedes proinflammatory, COX-mediated production of eicosanoids such as prostaglandins, which can further prevent neuronal damage [71, 72] .
Mitochondrial function
Mitochondrial dysfunction likely plays a vital role in the pathophysiology of ischemic and traumatic brain injury [85, 86, 87 ] . After stroke, mitochondrial function deteriorates as a direct result of impaired delivery of glucose and oxygen to the tissue and is further modified by changes in its properties that develop during I/R [52 ] . Mitochondria are the principal buffers of intracellular Ca 2þ and can become overloaded by cytoplasmic Ca 2þ flooding secondary to the opening of N-methyl-D-aspartate (NMDA) and voltage Ca 2þ channels. In I/R mitochondria lose their ability to modulate excessive Ca 2þ from cytoplasm, which further contributes to mitochondrial impairment. In addition, electron transport chain activity at the mitochondrial membrane deteriorates due to the release of cytochrome c through the outer mitochondrial membrane into the cytosol, and due to inhibition of mitochondrial enzymes such as pyruvate dehydrogenase. This is associated with loss of the metabolic cofactor NAD þ through the permeability transition pore (PTP) in the mitochondrial membrane [87 ] . Cytochrome c release is also induced by ROS associated with the release of Bax, Bak proapoptotic proteins [88] , which leads to activation of proapoptotic caspases, particularly caspase-3, resulting in chromatin condensation and DNA fragmentation [52 ,89] . ROS themselves are directly involved in oxidative damage such as lipid peroxidation, protein oxidation, protein nitrosylation/nitration, and nucleic acid damage in ischemic tissues, leading to cell death [52 ] .
Mitochondria regulate proapoptotic proteins such as cytochrome c, caspase-3 and caspase-9, and apoptosisinducing factor (AIF) [32, 90] . It is assumed that mechanisms by which NPD1/DHA offers neuroprotection for mitochondria involve induction of antiapoptotic Bcl-2 proteins and inhibition of apoptotic Bcl-2 proteins. These actions lead to downward release of cytochrome c from mitochondria, thereafter caspase-3 levels decrease [56] . Moreover, high intracellular Ca 2þ concentration and oxidative stress result in efflux of NAD þ to cell cytoplasm through the PTP, thereby reducing mitochondrial function [87 ,91] . Consequently, the ability to control intracellular Ca 2þ via DHA may indirectly provide an additional protective effect from this pathway. AIF and perhaps other proteins, which act independently of caspases, are released from mitochondria to the nucleus not long after I/R, and induce chromatin condensation and DNA fragmentation. These proteins have been implicated in focal ischemic damage as well. But little is known about the effects of DHA on these proteins [39, 56] .
Formation of free radicals
Under physiological conditions ROS, produced within cytoplasm and mitochondria are demolished rapidly by endogenous antioxidants. However, during H/I, the generation of ROS found in cytoplasm is increased in excess of the protective ability of the cells. These oxygen-free radicals contribute to tissue injury by activation of lipid peroxidation [producing malondialdehyde (MDA)], inflammatory mediators, and apoptosis [51, 81] . ROS could also result from depletion of antioxidant molecules such as reduced glutathione (GSH) and superoxide dismutase (SOD) [63] . Pan et al. [63] have shown that chronically (but not acutely) administered DHA could reduce MDA levels while enhancing SOD activity and increasing brain GSH levels after ischemic insult with a net result of reducing the oxidative burden in rat brain.
Inflammatory mediators
Leukocyte infiltration and products of proinflammatory gene expression are mediators of ischemic stroke damage [66] . Recently, it has been reported that in experimental stroke, DHA or NPD1 treatment is capable of decreasing polymorphonuclear leukocyte infiltration, and pro-inflammatory cytokines, such as interleukin 1 beta (IL-1b), IL-1 alpha (IL-1a), IL-6, inducible nitric oxide synthase and COX-2-induced prostaglandins, most of which are associated with arachidonic acid liberation after I/R injury [63, 66, 92, 93] . In addition, in vivo NPD1 potently inhibits nuclear factor kappa B (NF-kB), a transcription factor that plays an important role in inflammatory signaling pathways, controls several cytokines (e.g. IL-1, IL-2, IL-6, TNF-a), and inducible effector enzymes (e.g. inducible nitric oxide synthase and COX-2) [92, 93] . NF-kB is activated in I/R conditions similar to high COX-2 expression, which in turn generates PGH 2 , the substrate for prostaglandins synthetases and a contributor to oxidative stress [66] .
Cerebral infarction and docosahexaenoic acid
The mechanisms described above suggest how acute or chronic administration of DHA may contribute to ameliorating brain infarction. Neuroprotective effects of DHA can be documented after chronic supplementation prior to cerebral I/R, and involve improvement of hemodynamics, blockade of glutamatergic transmission, reduction of eicosanoid production, and enhancement of antioxidative capacity [39, 57, 58, 63, 73] . Pan et al. [63] have found that increases in DHA intake reduce postischemic brain infarction and edema, whether from a single intraperitoneal injection of DHA (100 or 500 nmol/kg) 1 h or 3 days prior to H/I, or from a daily intraperitoneal administration of DHA for 6 weeks prior to H/I. Likewise, other studies also confirm that repeated administration of n-3 FA exerts a beneficial effect on the ischemic brain under different protocols (e.g. 6-week supplement [73] , or 2-10-week gavages [39, 57, 58, 74] ).
The timing of DHA administration is likely important. In several animal models, DHA was given before and shortly after H/I insult; nevertheless, it may be difficult to apply these treatments in the context of acute stroke patients with a short therapeutic window [62, 63] . Of interest, other focal ischemia models have shown that benefit from DHA occurs if treatment takes place within 1-3 h after ischemia [61] [62] [63] .
Conclusion
Maintaining 'optimal' DHA levels in brain phospholipids relates to efficient regulation of brain synthetic, delivery, and catabolic pathways. Mechanisms of action by which DHA protects against cerebrovascular disease involve multiple mechanisms ranging from ion channels, to nuclear receptors. DHA, and in part through NPD1, its derivative docosanoid, provide neuroprotection both by antinecrotic and by antiapoptotic mechanisms (Table 2) . Most antinecrotic mechanisms of DHA involving neuroprotection were defined using protocols of acute or shortterm administration, while antiapoptotic activities of DHA are based on those using chronic or longer-term applications. We might predict from the present review that there are promising indications that supplementation with DHA, and perhaps other n-3 FA such as EPA may provide neuroprotective benefits at different ages from low birth weight infants to the elderly. Use of DHA as a supplement from both before and after an ischemic insult may help in primary prevention and secondary prevention.
A number of issues deserve additional investigation. For instance, it is still unclear whether increased dietary intake of n-3 FA in the absence of n-3 FA deficiency provides additional neuroprotective actions. In addition, before recommendations for clinical use, the choice of n-3 FA, EPA vs. DHA for example and doses must be defined and optimized. Will EPA have similar neuroprotective effects as DHA? Still, a large body of data suggest that the efficacy of n-3 FA, especially DHA, in inhibiting a large number of adverse pathways involved in cerebrovascular disease may lead to its use as a bioactive therapeutic agent for ischemic stroke.
